UNLABELLED: We report the results of alendronate ingestion plus exercise in preventing the declines in bone mass and strength and elevated levels of urinary calcium and bone resorption in astronauts during 5.5 months of spaceflight. INTRODUCTION: This investigation was an international collaboration between NASA and the JAXA space agencies to investigate the potential value of antiresorptive agents to mitigate the well-established bone changes associated with long-duration spaceflight. METHODS: We report the results from seven International Space Station (ISS) astronauts who spent a mean of 5.5 months on the ISS and who took an oral dose of 70 mg of alendronate weekly starting 3 weeks before flight and continuing throughout the mission. All crewmembers had available for exercise a treadmill, cycle ergometer, and a resistance exercise device. Our assessment included densitometry of multiple bone regions using X-ray absorptiometry (DXA) and quantitative computed tomography (QCT) and assays of biomarkers of bone metabolism. RESULTS: In addition to pre- and post-flight measurements, we compared our results to 18 astronauts who flew ISS missions and who exercised using an early model resistance exercise device, called the interim resistance exercise device, and to 11 ISS astronauts who exercised using the newer advanced resistance exercise device (ARED). Our findings indicate that the ARED provided significant attenuation of bone loss compared with the older device although post-flight decreases in the femur neck and hip remained. The combination of the ARED and bisphosphonate attenuated the expected decline in essentially all indices of altered bone physiology during spaceflight including: DXA-determined losses in bone mineral density of the spine, hip, and pelvis, QCT-determined compartmental losses in trabecular and cortical bone mass in the hip, calculated measures of fall and stance computed bone strength of the hip, elevated levels of bone resorption markers, and urinary excretion of calcium. CONCLUSIONS: The combination of exercise plus an antiresoptive drug may be useful for protecting bone health during long-duration spaceflight.
UNLABELLED: We report the results of alendronate ingestion plus exercise in preventing the declines in bone mass and strength and elevated levels of urinary calcium and bone resorption in astronauts during 5.5 months of spaceflight. INTRODUCTION: This investigation was an international collaboration between NASA and the JAXA space agencies to investigate the potential value of antiresorptive agents to mitigate the well-established bone changes associated with long-duration spaceflight. METHODS: We report the results from seven International Space Station (ISS) astronauts who spent a mean of 5.5 months on the ISS and who took an oral dose of 70 mg of alendronate weekly starting 3 weeks before flight and continuing throughout the mission. All crewmembers had available for exercise a treadmill, cycle ergometer, and a resistance exercise device. Our assessment included densitometry of multiple bone regions using X-ray absorptiometry (DXA) and quantitative computed tomography (QCT) and assays of biomarkers of bone metabolism. RESULTS: In addition to pre- and post-flight measurements, we compared our results to 18 astronauts who flew ISS missions and who exercised using an early model resistance exercise device, called the interim resistance exercise device, and to 11 ISS astronauts who exercised using the newer advanced resistance exercise device (ARED). Our findings indicate that the ARED provided significant attenuation of bone loss compared with the older device although post-flight decreases in the femur neck and hip remained. The combination of the ARED and bisphosphonate attenuated the expected decline in essentially all indices of altered bone physiology during spaceflight including: DXA-determined losses in bone mineral density of the spine, hip, and pelvis, QCT-determined compartmental losses in trabecular and cortical bone mass in the hip, calculated measures of fall and stance computed bone strength of the hip, elevated levels of bone resorption markers, and urinary excretion of calcium. CONCLUSIONS: The combination of exercise plus an antiresoptive drug may be useful for protecting bone health during long-duration spaceflight.
Authors: Suzanne M Schneider; William E Amonette; Kristi Blazine; Jason Bentley; Stuart M C Lee; James A Loehr; Alan D Moore; Michael Rapley; Edwin R Mulder; Scott M Smith Journal: Med Sci Sports Exerc Date: 2003-11 Impact factor: 5.411
Authors: Shreyasee Amin; David L Kopperdhal; L Joseph Melton; Sara J Achenbach; Terry M Therneau; B Lawrence Riggs; Tony M Keaveny; Sundeep Khosla Journal: J Bone Miner Res Date: 2011-07 Impact factor: 6.741
Authors: Shane A Lloyd; Sean E Morony; Virginia L Ferguson; Steven J Simske; Louis S Stodieck; Kelly S Warmington; Eric W Livingston; David L Lacey; Paul J Kostenuik; Ted A Bateman Journal: Bone Date: 2015-08-28 Impact factor: 4.398
Authors: Sandra L Poliachik; Tatiana D Khokhlova; Yak-Nam Wang; Julianna C Simon; Michael R Bailey Journal: Ultrasound Med Biol Date: 2014-05-21 Impact factor: 2.998
Authors: Mariya Stavnichuk; Nicholas Mikolajewicz; Tatsuya Corlett; Martin Morris; Svetlana V Komarova Journal: NPJ Microgravity Date: 2020-05-05 Impact factor: 4.415
Authors: Frank C Ko; Marie Mortreux; Daniela Riveros; Janice A Nagy; Seward B Rutkove; Mary L Bouxsein Journal: NPJ Microgravity Date: 2020-05-18 Impact factor: 4.415
Authors: Mark Shelhamer; Jacob Bloomberg; Adrian LeBlanc; G Kim Prisk; Jean Sibonga; Scott M Smith; Sara R Zwart; Peter Norsk Journal: NPJ Microgravity Date: 2020-02-12 Impact factor: 4.415
Authors: Sara R Zwart; Barbara L Rice; Holly Dlouhy; Linda C Shackelford; Martina Heer; Matthew D Koslovsky; Scott M Smith Journal: Am J Clin Nutr Date: 2018-05-01 Impact factor: 7.045